Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ombretta Lenzi is active.

Publication


Featured researches published by Ombretta Lenzi.


Journal of Medicinal Chemistry | 2009

2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A3 Adenosine Receptor Antagonists: New Insights into the Receptor-Antagonist Recognition

Ombretta Lenzi; Vittoria Colotta; Daniela Catarzi; Flavia Varano; Daniela Poli; Guido Filacchioni; Katia Varani; Fabrizio Vincenzi; Pier Andrea Borea; Silvia Paoletta; Erika Morizzo; Stefano Moro

A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A(3) adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic scaffold (R(5) = H, Me, Et, Ph, CH(2)Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA(3) adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (K(i) = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA(1), hA(2A), and hA(2B) adenosine receptors. On the basis of the recently published human A(2A) receptor crystallographic information, we propose a novel receptor-driven hypothesis to explain both A(3) AR affinity and A(3) versus A(2A) selectivity profiles of these new antagonists.


Bioorganic & Medicinal Chemistry | 2008

Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.

Vittoria Colotta; Daniela Catarzi; Flavia Varano; Ombretta Lenzi; Guido Filacchioni; Claudia Martini; Letizia Trincavelli; Osele Ciampi; Chiara Traini; Anna Maria Pugliese; Felicita Pedata; Erika Morizzo; Stefano Moro

The study of some 4-substituted-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives, designed as hA(3) adenosine receptor antagonists, is reported. The new compounds bear on the four-position different acylamino, sulfonylamino, benzylureido and benzyloxy moieties, which have also been combined with a para-methoxy group on the 2-phenyl ring or with a nitro residue at the six-position. Many derivatives show high hA(3) adenosine receptor affinities and selectivities both versus hA(1) and hA(2A) receptors. The observed structure-affinity relationships of this class of antagonists have been exhaustively rationalized using the recently published ligand-based homology modeling (LBHM) approach. The selected 4-bismethanesulfonylamino-2-phenyl-1,2,4-triazolo[4,3-a]quinoxalin-1-one (13), which shows high hA(3) affinity (K(i)=5.5nM) and selectivity versus hA(1), hA(2A) (both selectivity ratios>1800) and hA(2B) (cAMP assay, IC(50)>10,000nM) receptors, was tested in an in vitro rat model of cerebral ischemia, proving to be effective in preventing the failure of synaptic activity, induced by oxygen and glucose deprivation in the hippocampus, and in delaying the occurrence of anoxic depolarization.


Bioorganic & Medicinal Chemistry | 2011

Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo(3,4-c)quinoline derivatives as adenosine receptor antagonists

Ombretta Lenzi; Vittoria Colotta; Daniela Catarzi; Flavia Varano; Lucia Squarcialupi; Guido Filacchioni; Katia Varani; Fabrizio Vincenzi; Pier Andrea Borea; Diego Dal Ben; Catia Lambertucci; Gloria Cristalli

This paper reports the study of new 2-phenyl- and 2-methylpyrazolo[3,4-c]quinolin-4-ones (series A) and 4-amines (series B), designed as adenosine receptor (AR) antagonists. The synthesized compounds bear at the 6-position various groups, with different lipophilicity and steric hindrance, that were thought to increase human A(1) and A(2A) AR affinities and selectivities, with respect to those of the parent 6-unsubstituted compounds. In series A, this modification was not tolerated since it reduced AR affinity, while in series B it shifted the binding towards the hA(1) subtype. To rationalize the observed structure-affinity relationships, molecular docking studies at A(2A)AR-based homology models of the A(1) and A(3) ARs and at the A(2A)AR crystal structure were carried out.


European Journal of Medicinal Chemistry | 2012

3-Hydroxy-1H-quinazoline-2,4-dione derivatives as new antagonists at ionotropic glutamate receptors: molecular modeling and pharmacological studies.

Vittoria Colotta; Ombretta Lenzi; Daniela Catarzi; Flavia Varano; Lucia Squarcialupi; Chiara Costagli; Alessandro Galli; Carla Ghelardini; Anna Maria Pugliese; Giovanna Maraula; Elisabetta Coppi; Domenico E. Pellegrini-Giampietro; Felicita Pedata; Davide Sabbadin; Stefano Moro

Based on our 3-hydroxy-7-chloroquinazoline-2,4-dione derivatives, previously reported as antagonists at ionotropic glutamate receptors, we synthesized new 3-hydroxyquinazoline-2,4-diones bearing a trifluoromethyl group at the 7-position and different groups at position 6. Glycine/NMDA, AMPA and kainate receptor binding data showed that the 7-trifluoromethyl residue increased AMPA and kainate receptor affinity and selectivity, with respect to the 7-chlorine atom. Among the probed 6-substituents, the 6-(1,2,4-triazol-4-yl) group (compound 8) was the most advantageous for AMPA receptor affinity and selectivity. Derivative 8 demonstrated to be effective in decreasing neuronal damage produced by oxygen and glucose deprivation in organotypic rat hippocampal slices and also showed anticonvulsant effects in pentylenetetrazole-induced convulsions. The previously reported kainate receptor antagonist 6-(2-carboxybenzoyl)-amino-7-chloro-3-hydroxyquinazoline-2,4-dione 3 prevented the failure of neurotransmission induced by oxygen and glucose deprivation in the CA1 region of rat hippocampal slices.


Journal of Medicinal Chemistry | 2004

1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.

Vittoria Colotta; Daniela Catarzi; Flavia Varano; Francesca Romana Calabri; Ombretta Lenzi; Guido Filacchioni; Claudia Martini; Letizia Trincavelli; Francesca Deflorian


Bioorganic & Medicinal Chemistry | 2005

1-Substituted pyrazolo[1,5-c]quinazolines as novel Gly/NMDA receptor antagonists: Synthesis, biological evaluation, and molecular modeling study

Flavia Varano; Daniela Catarzi; Vittoria Colotta; Francesca Romana Calabri; Ombretta Lenzi; Guido Filacchioni; Alessandro Galli; Chiara Costagli; Francesca Deflorian; Stefano Moro


Journal of Medicinal Chemistry | 2007

New 2-Arylpyrazolo[3,4-c]quinoline Derivatives as Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand−Receptor Modeling Studies

Vittoria Colotta; Daniela Catarzi; Flavia Varano; Francesca Capelli; Ombretta Lenzi; Guido Filacchioni; Claudia Martini; Letizia Trincavelli; Osele Ciampi; Anna Maria Pugliese; Felicita Pedata; Andrea Schiesaro; Erika Morizzo; Stefano Moro


Journal of Medicinal Chemistry | 2006

4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as New Potent and Selective Human A3 Adenosine Receptor Antagonists. Synthesis, Pharmacological Evaluation, and Ligand−Receptor Modeling Studies

Ombretta Lenzi; Vittoria Colotta; Daniela Catarzi; Flavia Varano; Guido Filacchioni; Claudia Martini; Letizia Trincavelli; Osele Ciampi; Katia Varani; Federico Marighetti; Erika Morizzo; Stefano Moro


Journal of Medicinal Chemistry | 2006

Structural Investigation of the 7-Chloro-3-hydroxy-1H-quinazoline-2,4-dione Scaffold to Obtain AMPA and Kainate Receptor Selective Antagonists. Synthesis, Pharmacological, and Molecular Modeling Studies

Vittoria Colotta; Daniela Catarzi; Flavia Varano; Ombretta Lenzi; Guido Filacchioni; Chiara Costagli; Alessandro Galli; Carla Ghelardini; Nicoletta Galeotti; Paola Gratteri; Jacopo Sgrignani; Francesca Deflorian; Stefano Moro


Journal of Medicinal Chemistry | 2005

1,2,4-Triazolo[1,5-a]quinoxaline as a Versatile Tool for the Design of Selective Human A3 Adenosine Receptor Antagonists: Synthesis, Biological Evaluation, and Molecular Modeling Studies of 2-(Hetero)aryl- and 2-Carboxy-Substitued Derivatives

Daniela Catarzi; Colotta; Flavia Varano; Ombretta Lenzi; Guido Filacchioni; Letizia Trincavelli; Claudia Martini; Christian Montopoli; Stefano Moro

Collaboration


Dive into the Ombretta Lenzi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge